Hemophilia A medical therapy: Difference between revisions
(Created page with "__NOTOC__ {{Hemophilia A}} {{CMG}} ==Overview== ==Medical Therapy== Most haemophilia patients require regular supplementation with intravenous recombinant factor VIII...") |
m (Categories) |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
==Medical Therapy== | ==Medical Therapy== | ||
Most haemophilia patients require regular supplementation with [[intravenous]] [[recombinant]] factor VIII. This is highly individually determined. Apart from "routine" supplementation, extra factor concentrate is given around surgical procedures and after trauma. In children, an easily accessible intravenous port (e.g. [[Port-a-Cath]]) may have to be inserted to minimise frequent traumatic intravenous cannulation. These devices have made [[prophylaxis]] in hemophilia much easier for families because the problems of "finding a vein" for [[infusion]] two to three times a week are eliminated. However, there are risks involved with their use, the most worrisome being that of infection. Studies differ but some show an infection rate as high as 50 percent. These infections can usually be treated with [[intravenous]] antibiotics but sometimes the device must be removed. Also, there are other studies that show a risk of clots forming at the tip of the catheter. Still, many families have chosen to use the device in spite of the risk because of the benefits. Like any other procedure, one must weigh the risks and benefits. | Most haemophilia patients require regular supplementation with [[intravenous]] [[recombinant]] factor VIII. This is highly individually determined. Apart from "routine" supplementation, extra factor concentrate is given around surgical procedures and after trauma. In children, an easily accessible intravenous port (e.g. [[Port-a-Cath]]) may have to be inserted to minimise frequent traumatic intravenous cannulation. These devices have made [[prophylaxis]] in hemophilia much easier for families because the problems of "finding a vein" for [[infusion]] two to three times a week are eliminated. However, there are risks involved with their use, the most worrisome being that of infection. Studies differ but some show an infection rate as high as 50 percent. These infections can usually be treated with [[intravenous]] antibiotics but sometimes the device must be removed. Also, there are other studies that show a risk of clots forming at the tip of the catheter. Still, many families have chosen to use the device in spite of the risk because of the benefits. Like any other procedure, one must weigh the risks and benefits. | ||
| Line 17: | Line 18: | ||
{{WS}} | {{WS}} | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Pediatrics]] | [[Category:Pediatrics]] | ||
Revision as of 18:27, 17 June 2016
|
Hemophilia A Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hemophilia A medical therapy On the Web |
|
American Roentgen Ray Society Images of Hemophilia A medical therapy |
|
Risk calculators and risk factors for Hemophilia A medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
Most haemophilia patients require regular supplementation with intravenous recombinant factor VIII. This is highly individually determined. Apart from "routine" supplementation, extra factor concentrate is given around surgical procedures and after trauma. In children, an easily accessible intravenous port (e.g. Port-a-Cath) may have to be inserted to minimise frequent traumatic intravenous cannulation. These devices have made prophylaxis in hemophilia much easier for families because the problems of "finding a vein" for infusion two to three times a week are eliminated. However, there are risks involved with their use, the most worrisome being that of infection. Studies differ but some show an infection rate as high as 50 percent. These infections can usually be treated with intravenous antibiotics but sometimes the device must be removed. Also, there are other studies that show a risk of clots forming at the tip of the catheter. Still, many families have chosen to use the device in spite of the risk because of the benefits. Like any other procedure, one must weigh the risks and benefits.
Some may manage on desmopressin, if the clotting factor is still partially active.
A particular therapeutic conundrum is the development of "inhibitor" antibodies against factor VIII due to frequent infusions. These probably develop as the body recognises the factor VIII as foreign, as the body does not have its own "copy". The problem is that in these patients, factor VIII infusions are ineffective. Recently activated factor VII (NovoSeven®) has become available as a treatment for haemorrhage in patients with haemophilia and factor inhibitors.